This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shinoda, H. Articles by Tsuruo, T. Search for Related Content PubMed PubMed Citation Articles by Shinoda, H. Articles by Tsuruo, T.

In Vivo Circumvention of Vincristine Resistance in Mice with P388 Leukemia Using a Novel Compound, AHC-52¹

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Kami-Ikebukuro, Toshima-ku, Tokyo 170, Japan

A novel compound partially analogous to nifedipine, AHC-52, was found to sensitize multidrug-resistant tumor cells. AHC-52 at 0.5 µg/ml completely reversed the in vitro resistance to vincristine (VCR) in VCR-resistant P388 cells (P388/VCR). Of various regimens examined for the in vivo treatment of P388/VCR-bearing mice, the combination of 0.05 mg/kg of VCR with 100 mg/kg twice a day of AHC-52 daily demonstrated the best result with a 206% increase in life prolongation. This result was comparable with that observed in parental P388-bearing mice treated with the optimal dose of VCR alone, indicating almost complete circumvention of resistance by combination VCR-AHC-52 therapy. In addition, the combination of both agents exhibited therapeutic effects in the treatment of P388-bearing mice with some long term survivors. This result was presumably due to the elimination of heterogeneity of VCR sensitivity in this cell population. These results suggest that combination chemotherapy using a sensitizing agent such as AHC-52 will be effective in not only circumvention of multidrug resistance but also retardation of its occurrence.

¹ This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science, and Culture, Japan.

² Present address: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Nogi-machi, Tochigi 329-01, Japan.

³ To whom requests for reprints should be addressed.

Received 6/20/88. Revised 10/ 6/88. Revised 12/27/88. Accepted 1/ 5/89.

This article has been cited by other articles:

				Q. Mi, B. Cui, G. L. Silva, D. Lantvit, E. Lim, H. Chai, M. You, M. G. Hollingshead, J. G. Mayo, A. D. Kinghorn, et al. Pervilleine A, a Novel Tropane Alkaloid that Reverses the Multidrug-resistance Phenotype Cancer Res., May 1, 2001; 61(10): 4030 - 4037. [Abstract] [Full Text]

				H. TAKESHITA, M. C. GEBHARDT, D. S. SPRINGFIELD, K. KUSUZAKI, and H. J. MANKIN Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines J. Bone Joint Surg. Am., March 1, 1996; 78(3): 366 - 75. [Abstract] [Full Text]